Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing

Autor: Kazuhiro Imai, Yoshihiro Minamiya, Hiroshi Nanjo, Yoichi Akagami, Misako Yatsuyanagi, Yoshihiko Kimura, Yuki Wakamatsu, Shin-nosuke Watanabe, Eriko Takahashi, Satoru Motoyama, Yusuke Sato, Ryuta Nakamura, Chiaki Kudo, Ayano Ibonai, Shuichi Kamata, Ayuko Yamaguchi, Shinogu Takashima, Kyoko Nomura, Hikari Konno, Yoshihisa Katayose, Kaori Terata
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
0301 basic medicine
Cancer Research
Receptor
ErbB-2
Pleural effusion
Cytodiagnosis
Scoring criteria
Breast Neoplasms
In situ hybridization
lcsh:RC254-282
03 medical and health sciences
breast cancer
0302 clinical medicine
Breast cancer
Electricity
breast cancercytology
Cytology
medicine
Humans
Radiology
Nuclear Medicine and imaging
New device
In Situ Hybridization
Fluorescence
Original Research
Aged
Aged
80 and over
medicine.diagnostic_test
Diagnostic Tests
Routine
business.industry
Carcinoma
Ductal
Breast
human epidermal growth factor receptor 2
Clinical Cancer Research
Cancer
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
noncontact alternating current electric field mixing
Carcinoma
Lobular
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
cytology
Female
in situ hybridization
Nuclear medicine
business
Follow-Up Studies
Fluorescence in situ hybridization
Zdroj: Cancer Medicine, Vol 10, Iss 2, Pp 586-594 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Human epidermal growth factor receptor 2‐in situ hybridization (HER2‐ISH) is widely approved for diagnostic, prognostic biomarker testing of formalin‐fixed paraffin‐embedded tissue blocks. However, cytologic ISH analysis has a potential advantage in tumor samples such as pleural effusion and ascites that are difficult to obtain the histological specimens. Our aim was to evaluate the clinical reliability of a novel rapid cytologic HER2 fluorescence ISH protocol (rapid‐CytoFISH). Materials and Methods Using a new device, we applied a high‐voltage/frequency, noncontact alternating current electric field to tissue imprints and needle rinses, which mixed the probe within microdroplets as the voltage was switched on and off (AC mixing). Cytologic samples (n = 143) were collected from patients with immunohistochemically identified HER2 breast cancers. The specimens were then tested using standard dual‐color ISH using formalin‐fixed paraffin‐embedded tissue (FFPE‐tissue DISH) for HER2‐targeted therapies, CytoFISH, and rapid‐CytoFISH (completed within 4 h). Results All 143 collected cytologic specimens (50 imprinted cytology specimens from resected tumors and 93 liquid‐based cytology specimens from needle rinses) were suitable for FISH analysis. The HER2/chromosome enumeration probe (CEP) 17 ratios did not significantly differ between FFPE‐tissue DISH and either CytoFISH protocol. Based on HER2 scoring criteria, we found 95.1% agreement between FFPE‐tissue DISH and CytoFISH (Cohen's kappa coefficient = 0.771 and 95% confidence interval (CI): 0.614–0.927). Conclusion CytoFISH could potentially serve as a clinical tool for prompt determination of HER2 status in breast cancer cytology. Rapid‐CytoFISH with AC mixing will enable cancer diagnoses and HER2 status to be determined on the same day a patient comes to a clinic or hospital.
Rapid in situ hybridization device used to apply an alternating current electric field analysis of cytologic specimens (Rapid CytoFISH) has a potential advantage in tumor samples such as pleural effusion and ascites that are difficult to obtain the histological specimens. Rapid‐CytoFISH will enable cancer diagnoses and Human epidermal growth factor receptor 2 (HER2) status to be determined on the same day a patient comes to a clinic or hospital.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje